AstraZeneca announced a significant $50 billion investment in the US on July 21, 2025, with plans to implement the investment over the next five years, through 2030. The goal of this calculated action is to strengthen America’s dominant position in pharmaceutical R&D and manufacturing.
For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation’s new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here.
Howard Lutnick
Read More: AstraZeneca’s Datroway Receives US Approval for EGFR-Mutated Lung Cancer
Key highlights of the investment
- New Manufacturing Facility: Building a brand-new, multibillion-dollar drug substance manufacturing facility in the Commonwealth of Virginia is a significant component of this investment. Dedicated to creating cutting-edge treatments for metabolic disorders and weight control, this facility will be AstraZeneca’s largest single investment in a manufacturing site worldwide.
- Revenue Growth and Job Creation: It is anticipated that the investment would result in a sizable number of highly skilled jobs. Additionally, it will help AstraZeneca achieve its target of $80 billion in total revenue by 2030, of which half is expected to originate from the US market.
- Technological Advancement: To enhance production processes, the new Virginia plant will integrate cutting-edge technology such as automation, data analytics, and artificial intelligence (AI).
- Manufacturing and R&D Facility Expansion: The investment will also support the growth of manufacturing and research facilities in Massachusetts and Maryland. It will also help Maryland and California establish next-generation cell therapy manufacturing facilities.
- Government Support: The US Secretary of Commerce and the Governor of Virginia both made encouraging remarks in the press release, stressing the investment’s positive effects on the US economy and domestic supply chain.
Read More: AstraZeneca’s Tagrisso with Chemotherapy Shows Significant Survival Benefit in Advanced Lung Cancer
Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia’s desire to create highly skilled jobs in science and technology, and will strengthen the country’s domestic supply chain for medicines.
Pascal Soriot
Last Modified:
